Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Corvus Pharmaceuticals, Inc. (CRVS)
|
Add to portfolio |
|
|
|
| Price: |
$2.74
| | Metrics |
| OS: |
49.0
|
M
| |
|
|
| Market cap: |
$134
|
M
| |
|
|
|
Net cash:
|
$7.66
|
M
| |
$0.16
|
per share
|
|
EV:
|
$127
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Research and development | 29.1 | 31.8 | 38.0 | 38.6 | 46.3 | 29.4 | 11.4 |
| General and administrative | 9.5 | 11.9 | 10.9 | 10.6 | 10.2 | 7.6 | 2.4 |
| EBIT | -38.6 | -6.3 | -48.9 | -49.2 | -56.5 | -37.0 | -13.8 |
| Pre-tax income | -43.2 | -6.0 | -46.7 | -46.9 | -55.7 | -36.4 | -31.3 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -43.2 | -6.0 | -46.7 | -46.9 | -55.7 | -36.4 | -31.3 |
| |
| Diluted EPS | ($1.03) | ($0.20) | ($1.59) | ($1.71) | ($2.72) | ($2.36) | ($83.86) |
| Shares outstanding (diluted) | 41.9 | 29.5 | 29.3 | 27.5 | 20.5 | 15.4 | 0.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|